Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS AK Ghosh, HL Osswald, G Prato Journal of medicinal chemistry 59 (11), 5172-5208, 2016 | 439 | 2016 |
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease AK Ghosh, HL Osswald Chemical Society Reviews 43 (19), 6765-6813, 2014 | 366 | 2014 |
Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals S Tomar, ML Johnston, SES John, HL Osswald, PR Nyalapatla, LN Paul, ... Journal of Biological Chemistry 290 (32), 19403-19422, 2015 | 154 | 2015 |
Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance X Deng, SE StJohn, HL Osswald, A O'Brien, BS Banach, K Sleeman, ... Journal of Virology 88 (20), 11886-11898, 2014 | 103 | 2014 |
Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants AK Ghosh, KV Rao, PR Nyalapatla, HL Osswald, CD Martyr, M Aoki, ... Journal of medicinal chemistry 60 (10), 4267-4278, 2017 | 78 | 2017 |
A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant S Agnihothram, BL Yount Jr, EF Donaldson, J Huynh, VD Menachery, ... MBio 5 (2), 10.1128/mbio. 00047-14, 2014 | 59* | 2014 |
Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies AK Ghosh, GL Parham, CD Martyr, PR Nyalapatla, HL Osswald, ... Journal of medicinal chemistry 56 (17), 6792-6802, 2013 | 51 | 2013 |
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency M Aoki, H Hayashi, KV Rao, D Das, N Higashi-Kuwata, H Bulut, ... Elife 6, e28020, 2017 | 49 | 2017 |
Design of Highly Potent, Dual‐Acting and Central‐Nervous‐System‐Penetrating HIV‐1 Protease Inhibitors with Excellent Potency against Multidrug‐Resistant HIV‐1 Variants AK Ghosh, KV Rao, PR Nyalapatla, S Kovela, M Brindisi, HL Osswald, ... ChemMedChem 13 (8), 803-815, 2018 | 40 | 2018 |
Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure–activity studies, biological and x-ray … AK Ghosh, P R. Nyalapatla, S Kovela, KV Rao, M Brindisi, HL Osswald, ... Journal of medicinal chemistry 61 (10), 4561-4577, 2018 | 36 | 2018 |
X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design SES John, MD Therkelsen, PR Nyalapatla, HL Osswald, AK Ghosh, ... Bioorganic & medicinal chemistry letters 25 (22), 5072-5077, 2015 | 29 | 2015 |
Simultaneous online monitoring of multiple reactions using a miniature mass spectrometer CJ Pulliam, RM Bain, HL Osswald, DT Snyder, PW Fedick, ST Ayrton, ... Analytical chemistry 89 (13), 6969-6975, 2017 | 27 | 2017 |
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: Synthesis, biological evaluation, and enzyme–inhibitor X-ray structural studies AK Ghosh, X Yu, HL Osswald, J Agniswamy, YF Wang, M Amano, ... Journal of medicinal chemistry 58 (13), 5334-5343, 2015 | 25 | 2015 |
Structure-based design of highly potent HIV-1 protease inhibitors containing new tricyclic ring P2-ligands: design, synthesis, biological, and X-ray structural studies AK Ghosh, S Kovela, HL Osswald, M Amano, M Aoki, J Agniswamy, ... Journal of medicinal chemistry 63 (9), 4867-4879, 2020 | 22 | 2020 |
The design, development, and evaluation of BACE1 inhibitors for the treatment of Alzheimer’s disease AK Ghosh, EL Cárdenas, HL Osswald Alzheimer’s Disease II, 27-85, 2017 | 22 | 2017 |
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1–P2 ligands AK Ghosh, GE Schiltz, LN Rusere, HL Osswald, DE Walters, M Amano, ... Organic & biomolecular chemistry 12 (35), 6842-6854, 2014 | 19 | 2014 |
Probing lipophilic adamantyl group as the P1-ligand for HIV-1 protease inhibitors: design, synthesis, protein X-ray structural studies, and biological evaluation AK Ghosh, HL Osswald, K Glauninger, J Agniswamy, YF Wang, ... Journal of medicinal chemistry 59 (14), 6826-6837, 2016 | 16 | 2016 |
Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and … AK Ghosh, CD Martyr, HL Osswald, VR Sheri, LA Kassekert, S Chen, ... Journal of medicinal chemistry 58 (17), 6994-7006, 2015 | 14 | 2015 |
Ligand-induced dimerization of MERS coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals S Tomar, ML Johnston, SE St John, HL Osswald, PR Nyalapatla, LN Paul, ... J Biol Chem 290, 19403-19422, 2015 | 8 | 2015 |
Enantioselective synthesis of dioxatriquinane structural motifs for HIV-1 protease inhibitors using a cascade radical cyclization AK Ghosh, CX Xu, HL Osswald Tetrahedron letters 56 (23), 3314-3317, 2015 | 7 | 2015 |